Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Sponsor: Guizhou Provincial People's Hospital
Summary
Cervical cancer CC is the most common malignant tumor in the female reproductive system, seriously endangering women's health and life, and is one of the leading causes of death for women worldwide.Globally, HPV causes about 85% of cervical cancers and about 60% of oropharyngeal cancers, causing more than 500,000 cancers each year.ctDNA is a potential biomarker because it contains tumor-specific genetic and epigenetic abnormalities that can be used in cancer diagnosis and prognosis prediction.MRD is considered a promising prognostic marker that can be used to identify individuals at increased risk of recurrence and individuals who may benefit from treatment.The expression level of MRD and plasma HPV before and after radiotherapy and chemotherapy for cervical cancer was analyzed by liquid biopsy ctDNA detection technology, which predicted the efficacy of cervical cancer radiotherapy and chemotherapy, which was helpful for monitoring and estimating the risk of disease recurrence after cervical cancer radiotherapy and chemotherapy, and verified the expression of MRD and plasma HPV as the basis for adjuvant chemotherapy after cervical cancer radiotherapy and the basis for optimal chemotherapy time node selection.
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
OBSERVATIONAL
Enrollment
30
Start Date
2022-11-01
Completion Date
2026-12-31
Last Updated
2023-07-18
Healthy Volunteers
No
Conditions
Interventions
Concurrent chemoradiotherapy
Concurrent chemoradiotherapy
Locations (1)
Yong Li
Guiyang, Guizhou, China